NEW YORK (GenomeWeb) - Biocept reported today after the close of the market that its first quarter revenues rose to $150,000 compared to $28,000 in Q1 2014, with the increase primarily due to growing commercial liquid biopsy test volumes.

The San Diego-based firm, which sells molecular diagnostic tests based on circulating tumor cells and circulating tumor DNA, said it tested 247 commercial cases during the first quarter of 2015, up from 11 commercial cases during the first quarter of 2014.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.